Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
- None.
- None.
Conference Call Scheduled for Tuesday, August 15 at 11:30 AM EDT
NORTHVALE, NJ / ACCESSWIRE / August 14, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the first quarter of fiscal year 2024 ended June 30, 2023 ("First Quarter").
Consolidated revenues for the three-month period ended June 30, 2023, were
Conference Call Information
Elite's management will host a conference call to discuss the First Quarter financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.
Date: | August 15, 2023 |
Time: | 11:30 AM EDT |
Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
Conference number: | 98840 |
Questions: | dianne@elitepharma.com Financial questions by 7:00 PM EST on Monday, August 14, 2023 |
Audio Replay: | https://elite.irpass.com/events_presentations |
The financial statements can be viewed for Elite's First Quarter of Fiscal Year 2024 on Form 10-Q here.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite's product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
SOURCE: Elite Pharmaceuticals, Inc.
View source version on accesswire.com:
https://www.accesswire.com/774100/Elite-Pharmaceuticals-Inc-Reports-Financial-Results-for-First-Quarter-of-Fiscal-Year-2024-ended-June-30-2023-and-Provides-Conference-Call-Information
FAQ
What is the name of the company mentioned in the press release?
What is the stock ticker symbol of Elite Pharmaceuticals, Inc.?
When did the first quarter of fiscal year 2024 end?
What was the percentage increase in consolidated revenues for the first quarter?
What was the percentage increase in operating profits for the first quarter?
What was the percentage increase in net income attributable to common shareholders for the first quarter?
What was the reason for the increase in operating profits?
When is the conference call scheduled to discuss the first quarter financial results?
How can stockholders submit questions for the conference call?
Where can the financial statements for the first quarter be viewed?
What are the dial-in numbers for the conference call?
What is the conference number for the call?
What is the deadline for submitting financial questions?